Hereditary Thyroid Cancer Panel, Sequencing and Deletion/Duplication
Recommended test to confirm a hereditary cause of thyroid cancer in individuals with a personal or family history of thyroid cancer.
To compare this test to other hereditary cancer panels, refer to the ARUP Hereditary Cancer Panel Comparison table.
New York DOH Approval Status
Lavender or pink (EDTA) or yellow (ACD Solution A or B).
New York State Clients: Lavender (EDTA)
Transport 3 mL whole blood. (Min: 2 mL)
New York State Clients: 5 mL (Min: 2 mL)
Serum or plasma; grossly hemolyzed or frozen specimen; saliva; buccal brush, or swab; FFPE tissue.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
New York State Clients: Ambient: 24 hours; Refrigerated: 1 week; Frozen: Unacceptable
Massively Parallel Sequencing/Sequencing
Refer to report.
Laboratory Developed Test (LDT)
GENES TESTED: APC*; DICER1; MEN1*; PRKAR1A; PTEN*; RET; TP53
*One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see Additional Technical Information.
81201; 81203; 81404; 81405; 81321; 81323; 81406; 81351; 81479
|Component Test Code*||Component Chart Name||LOINC|
- Cowden syndrome
- Familial adenomatous polyposis
- Familial medullary thyroid carcinoma (FMTC)
- Familial thyroid cancer
- Li-Fraumeni syndrome
- Medullary carcinoma of the thyroid
- Multiple endocrine neoplasia